David A. Frank, MD, PhD, FACP
-
RoleHematology
-
Specialty
-
Research Program
-
Practicing Since1993
Rating: 4.9 out of 5 (110 ratings)
David A. Frank, MD, PhD, FACP, is the director of the Division of Hematology and a professor in Emory University School of Medicine's Department of Hematology and Medical Oncology. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center. Board certified in medical oncology, he cares for patients with hematologic malignancies, specializing in leukemia. He is actively involved in training the next generation of clinical oncologists and cancer scientists.
Prior to joining Emory, Dr. Frank was the chief quality officer for Dana-Farber/Harvard Cancer Center, having previously served as chair of Quality Improvement for Medical Oncology, chair of the Pharmacy and Therapeutics Committee, and medical director of patient safety.
Dr. Frank received his MD and PhD from Yale University. After serving as an intern, resident, and chief resident in internal medicine at Yale, he completed training in medical oncology at Dana-Farber Cancer Institute, followed by a postdoctoral fellowship in intracellular signal transduction at Harvard Medical School.
A renowned physician-scientist, Dr. Frank's translational research laboratory focuses on the intracellular signaling pathways that control normal cellular function and become subverted in the development of cancer, and then using this knowledge in designing targeted molecular inhibitors for the treatment of cancer. His lab has developed innovative ways to target STAT transcription factors, leading to a series of therapeutic clinical trials, including the first clinical trial of a small molecule STAT3 inhibitor in cancer therapy.
Dr. Frank has authored or coauthored more than 100 peer-reviewed publications. He serves on the editorial board of Cancer Research, Clinical Cancer Research, and Cancer Biology and Therapy. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, Nature Medicine, Science Signaling, Proceedings of the National Academy of Sciences, and others. PubMed
Dr. Frank is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. He is a Fellow of American College of Physicians. He holds professional memberships with American Association for the Advancement of Science, American Association of Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Microbiology. He serves as chair for the Medical Sciences Section of the American Association for the Advancement of Science.
Title/Journal | Authors | Publication Date |
---|---|---|
Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research |
MJ Hochman, DA Frank | 10/15/2024 |
Cancers |
W Wang, MC Lopez McDonald, R Hariprasad, T Hamilton, DA Frank | 03/31/2024 |
European journal of medicinal chemistry |
JI Brown, R Persaud, P Iliev, U Karmacharya, S Attarha, H Sahile, JE Olsen, D Hanke, T Idowu, DA Frank, A Frankel, KC Williams, BDG Page | 01/15/2024 |
Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers. Breast cancer research : BCR |
CA Hathaway, MS Rice, LC Collins, D Chen, DA Frank, S Walker, CV Clevenger, RM Tamimi, SS Tworoger, SE Hankinson | 03/07/2023 |
Clinical cancer research : an official journal of the American Association for Cancer Research |
EC Chen, H Gandler, I Tošić, GG Fell, A Fiore, O Pozdnyakova, DJ DeAngelo, I Galinsky, MR Luskin, M Wadleigh, ES Winer, R Leonard, K O'Day, A de Jonge, D Neuberg, AT Look, RM Stone, DA Frank, JS Garcia | 03/01/2023 |
Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity. Metabolites |
JI Brown, P Wang, AYL Wong, B Petrova, R Persaud, S Soukhtehzari, M Lopez McDonald, D Hanke, J Christensen, P Iliev, W Wang, DK Everton, KC Williams, DA Frank, N Kanarek, BDG Page | 01/19/2023 |
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States. Cancer research |
LE Stevens, G Peluffo, X Qiu, D Temko, A Fassl, Z Li, A Trinh, M Seehawer, B Jovanović, M Alečković, CM Wilde, RC Geck, S Shu, NL Kingston, NW Harper, V Almendro, AL Pyke, SB Egri, M Papanastasiou, K Clement, N Zhou, S Walker, J Salas, SY Park, DA Frank, A Meissner, JD Jaffe, P Sicinski, A Toker, F Michor, HW Long, BA Overmoyer, K Polyak | 01/18/2023 |
Frontiers in immunology |
W Wang, MC Lopez McDonald, C Kim, M Ma, ZT Pan, C Kaufmann, DA Frank | 01/01/2023 |
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. Molecular oncology |
Y Yoshikawa, KH Stopsack, XV Wang, YH Chen, YZ Mazzu, F Burton, G Chakraborty, SH Rajanala, R Hirani, S Nandakumar, GM Lee, D Frank, E Davicioni, G Liu, MA Carducci, H Azuma, PW Kantoff, CJ Sweeney | 12/01/2022 |
Cell reports |
AK Ajay, L Zhao, S Vig, M Fujiwara, S Thakurela, S Jadhav, A Cho, IJ Chiu, Y Ding, K Ramachandran, A Mithal, A Bhatt, P Chaluvadi, MK Gupta, SI Shah, VS Sabbisetti, AM Waaga-Gasser, DA Frank, G Murugaiyan, JV Bonventre, LL Hsiao | 03/08/2022 |
The Journal of biological chemistry |
LN Heppler, S Attarha, R Persaud, JI Brown, P Wang, B Petrova, I Tošić, FB Burton, Y Flamand, SR Walker, JE Yeh, RA Zubarev, M Gaetani, N Kanarek, BDG Page, DA Frank | 02/01/2022 |
STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications. Neoplasia (New York, N.Y.) |
I Tošić, DA Frank | 12/01/2021 |
Disease models & mechanisms |
L Wang, M Astone, SK Alam, Z Zhu, W Pei, DA Frank, SM Burgess, LH Hoeppner | 11/01/2021 |
Proceedings of the National Academy of Sciences of the United States of America |
F Valença-Pereira, Q Fang, IJ Marié, EL Giddings, KA Fortner, R Yang, AV Villarino, YH Huang, DA Frank, H Wen, DE Levy, M Rincon | 09/14/2021 |
British journal of cancer |
M Lapidot, AE Case, EL Weisberg, C Meng, SR Walker, S Garg, W Ni, K Podar, YP Hung, RD Carrasco, A Knott, PC Gokhale, S Sharma, A Pozhitkov, P Kulkarni, DA Frank, R Salgia, JD Griffin, SV Saladi, R Bueno, M Sattler | 08/01/2021 |
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.
4.9 |
| Provider showed concern |
4.9 |
| Provider explained things clearly |
4.9 |
| Provider discussed treatment options |
4.9 |
| Provider included you in decisions |
5 |
| Likelihood of recommending this provider |
|
11/02/2024 |
Dr. Frank and the team did an amazing job. They worked very well together and spent so much time explaining everything |
|
10/16/2024 |
Great first visit |
|
09/07/2024 |
Dr. Frank was good in appreciating my concerns. |
|
07/18/2024 |
Dr Frank is the best Dr I have ever seen. Competent, knowledgeable, kind, compassionate. He truly cares about his patients and has the vast knowledge to treat them effectively. |
|
05/30/2024 |
Dr. Frank was very easy to talk with and was good at answering my questions. |
|
02/24/2024 |
Dr. Frank is very patient and very thorough. |
|
02/08/2024 |
Dr. Frank was kind and patient!! He explained everything in great detail. And listened to my concerns. I think he is one of the nicest and best doctors I have ever seen and I am glad to be his patient. |
|
01/18/2024 |
Good |
|
01/11/2024 |
Dr. Frank was thorough, detail oriented, an excellent listener and an excellent communicator in explaining my condition and treatment options. |
|
12/09/2023 |
Dr Frank is outstanding. He was attentive to my needs, allowed me to ask any questions I wanted, and answered each to my satisfaction. He is not only rigorous and exacting In WHAT he describes but exceptionally compassion in HOW he discusses sensitive topics. I am grateful to have him leading my team. |
|
12/07/2023 |
Always clear, concise discussions about procedure, etc.. |
|
10/12/2023 |
One of the best doctors I have ever used for treating me |
|
09/14/2023 |
Dr. Frank is the best communicator/listener always so thoughtful, insightful, calming and caring. I am so lucky he has been my Dr. Through my Cancer struggles. |
|
07/16/2023 |
Dr.Frank is a superb listener and that is, in my opinion, essential to successfully treating any illness or concern. |
|
07/07/2023 |
Excellent! Dr Frank gave me a thorough exam, asked lots of questions, then gave me a detailed description of my condition and what to expect then answered all our questions |
|
07/06/2023 |
Could not have better |
|
06/22/2023 |
Even for complex issues Dr explained in English what was happening and why. |
|
06/17/2023 |
Good |
|
06/15/2023 |
Genuine concern was expressed for my care & treatment. |
|
06/10/2023 |
Dr. Frank was fantastic |
|
05/25/2023 |
My Oncologist and his team are amazing ...Cancer is a horrible diagnosis but they make it less scary and I feel so supported by Dr.Frank and his team of Drs and nurses Yes I would reffer his office and Emory to anyone who is going thu what I am going thu |
|
05/06/2023 |
In my lifetime experiences, Dr. Frank is probably the most caring physician I have encountered. Even dealing with so many patients, many with more critical illnesses, he gives me his undivided attention. It is extraordinary in today's practice of medicine. |
|
05/06/2023 |
Very Good. |
|
01/27/2023 |
We were referred to Doc to verify condition set plan going forward. |